구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Certolizumab pegol (Certolizumab pegol) Mario Negri Institute for Pharmaco…·Crohn's Disease 60 trials·t½ 14 h |
|---|---|
Overview Program | Certolizumab pegol |
Overview Company | Mario Negri Institute for Pharmacological Research |
Overview Modality | ANTIBODY |
Overview Target | Crohn's Disease |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | Novelty assessment and Weibull modeling were applied to characterize signal strength and temporal risk patterns, acknowledgin |
MoA Mechanism | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | biomarkers (including sFlt-1/PlGF), standardized endpoints, and detailed safety follow-up are needed before a |
PK/PD Half-life | 14 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Pharmacokinetics of Certolizumab Pegol in Pregnancy: Results from the Open-Label CHERISH Study.. Control of chronic inflammatory diseases (CIDs) during pregnancy is essential for maternal and foetal health; however, the impact of pregnancy on the pharmacokinetics (PK) of CID therapies is unknown. This study investigated the impact of pregnancy on the PK of certolizumab pegol (CZP), a tumour necros… |
Clinical Safety signal | Pharmacokinetics of Certolizumab Pegol in Pregnancy: Results from the Open-Label CHERISH Study.. Control of chronic inflammatory diseases (CIDs) during pregnancy is essential for maternal and foetal health; however, the impact of pregnancy on the pharmacokinetics (PK) of CID therapies is unknown. This study investigated the impact of pregnancy on the PK of certolizumab pegol (CZP), a tumour necros… |
Clinical Result source | ClinicalTrials.gov NCT00845663 |
Clinical Program phase | APPROVED |
Clinical Trial ref | NCT00845663 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Certolizumab pegol (Certolizumab pegol) Mario Negri Institute for Pharmaco…·Crohn's Disease 60 trials·t½ 14 h |
|---|---|
Overview Program | Certolizumab pegol |
Overview Company | Mario Negri Institute for Pharmacological Research |
Overview Modality | ANTIBODY |
Overview Target | Crohn's Disease |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | Novelty assessment and Weibull modeling were applied to characterize signal strength and temporal risk patterns, acknowledgin |
MoA Mechanism | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | biomarkers (including sFlt-1/PlGF), standardized endpoints, and detailed safety follow-up are needed before a |
PK/PD Half-life | 14 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Pharmacokinetics of Certolizumab Pegol in Pregnancy: Results from the Open-Label CHERISH Study.. Control of chronic inflammatory diseases (CIDs) during pregnancy is essential for maternal and foetal health; however, the impact of pregnancy on the pharmacokinetics (PK) of CID therapies is unknown. This study investigated the impact of pregnancy on the PK of certolizumab pegol (CZP), a tumour necros… |
Clinical Safety signal | Pharmacokinetics of Certolizumab Pegol in Pregnancy: Results from the Open-Label CHERISH Study.. Control of chronic inflammatory diseases (CIDs) during pregnancy is essential for maternal and foetal health; however, the impact of pregnancy on the pharmacokinetics (PK) of CID therapies is unknown. This study investigated the impact of pregnancy on the PK of certolizumab pegol (CZP), a tumour necros… |
Clinical Result source | ClinicalTrials.gov NCT00845663 |
Clinical Program phase | APPROVED |
Clinical Trial ref | NCT00845663 |
추천 비교
추천 비교